Pneumococcal vaccine conjugate 13-valent - Pfizer
Alternative Names: 13-Valent pneumococcal conjugate vaccine - Pfizer; 13vPnC; PCV 13; PNCRM13; Pneumococcal 13-valent conjugate vaccine - Pfizer; Pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed) - Pfizer; Prevenar 13; Prevnar 13Latest Information Update: 09 May 2024
At a glance
- Originator Wyeth
- Developer Cochin Hospital; Pfizer; University Hospital of Montpellier; Wyeth
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Pneumococcal infections
Most Recent Events
- 13 Oct 2023 Pfizer completes a phase III trial for Pneumococcal-infections (Prevention, In infants, In children) in China (IM) (NCT03574389)
- 31 Dec 2022 The European Patent Office revokes European patent related to 13-valent pneumococcal conjugate vaccine , prior to December 2022
- 04 Nov 2022 Pfizer initiates enrolment in a phase III trial for Pneumococcal infections (In infants, Prevention) in China(IM) (NCT05759520)